24/7 Wall Street
01 Sept 2026, 12:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Amgen raised its full-year revenue guidance to $38.2-$39.4 billion and non-GAAP EPS to $22.30-$23.50. — Upward revisions to top and bottom-line guidance typically trigger positive price action as they signal stronger-than-expected fundamentals.
+0.60Repatha delivered $953 million in Q2 sales, representing a 37% year-over-year increase and over 50% growth in U.S. new prescriptions. — Strong growth in a core product demonstrates commercial scalability and provides a tangible catalyst for the company's valuation.
+0.50Amgen trades at a forward P/E of 19, significantly lower than Eli Lilly's forward P/E of 32. — A lower valuation relative to a peer in a high-growth sector suggests potential for multiple expansion if the market re-rates the stock.
+0.30Continue reading
6 related stories
Search tags
Repatha faces commercial headwinds due to resistance from insurance companies regarding reimbursement. — Payer resistance can create a ceiling on revenue growth regardless of the drug's clinical efficacy.
-0.30Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
2h ago
